In 2020, a literature review examined the correlation between PR3-ANCA and different IBD clinical characteristics [14] and confirmed that this biomarker could represent an important tool to support IBD diagnosis in the discrimination between UC and CD and for prognosis (disease extent and severity). Here, PRTN3 is linked to inflammatory bowel disease.